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Abstract The cyclin-dependent kinase (CDK) inhibitor 
p21Cipl consists of two domains that interact with CDKs and 
proliferating cell nuclear antigen (PCNA), respectively. We have 
investigated the interaction between p21Cipl and PCNA using 
surface plasmon resonance (SPR) technology and compared the 
results with those obtained from other sources such as the yeast 
two-hybrid system. Whilst other methods are only semi- 
quantitative, the SPR technique allowed us to determine the 
kinetic parameters of the interaction. The apparent equilibrium 
constant KD calculated for these kinetic parameters was 
3.2 X 10 -7 M. We further demonstrate the use of SPR to study 
the interaction between mutant proteins and to determine their 
actual KD. The interaction between p21Cipl/PCNA is shown to 
be dependent upon the trimeric conformation of PCNA since a 
point mutant that abolishes PCNA-PCNA interaction also 
abolishes PCNA's interaction with p21Cipl. Finally, we 
demonstrate that SPR can be used to characterise the interaction 
of p21Cipl and PCNA in the presence of short competitive 
peptides. 
Key words: PCNA; Cyclin-dependent kinase inhibitor; 
p21Cipl/Wafl ; Cell cycle 
1. Introduction 
Cyclin-dependent kinases (CDKs) regulate the key transi- 
tions of the eukaryotic ell cycle. Their activities are regulated 
at different levels [1] including specific inhibitors called cyclin- 
dependent kinase inhibitors (CKIs), which have been identi- 
fied by virtue of their physical interaction with the CDKs. The 
inhibitor p21Cipl/WAF1 plays an important growth control 
function by arresting the cell cycle in Gl-phase in response to 
extra- or intracellular signals such as DNA damage [2]. 
p21Cipl has been shown to interact both with the CDK2 
kinase and with proliferating cell nuclear antigen (PCNA) 
an auxiliary protein of DNA polymerase ~5 [3]. 
In order to identify the p21Cipl inhibitor domains that are 
involved in the interaction with CDK2 and with PCNA,  we 
performed extensive mutagenesis using the alanine-scanning 
mutagenesis strategy [4]. A large number of p21 mutants 
were produced as fusion proteins with GST (glutathione S- 
transferase), purified and used in an in vitro interaction assay 
with either in vitro translated CDK2 or purified PCNA, This 
work led to the identification of several mutants that were 
deficient for either of these interactions and suggested that 
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binding domains for both partners of p21Cipl were localised 
to the amino- and carboxy-terminal parts of the protein, re- 
spectively [4]. Other groups used different approaches to reach 
similar conclusions [5-7]. 
Recent advances in our understanding of the molecular 
basis of growth control suggest hat cyclin-dependent kinases 
and their regulators, i.e. inhibitors such as p21Cipl, might 
represent potential targets for new pharmacological strategies. 
However, molecular interactions between cell cycle regulators 
are generally analysed at a superficial level. In particular, the 
kinetics and thermodynamics of the interactions are rarely 
characterised, information that is essential for the develop- 
ment of screening strategies designed to identify modulators 
and ultimately to aid rational drug design. 
The BIAcore (Pharmacia Biosensor) is a surface plasmon 
resonance (SPR)-based system for real time analysis of bio- 
specific interactions [8]. To study the interactions between 
biomolecules, the BIAcore system uses an optical technique 
that measures the refractive index at the sensor chip surface. 
A ligand is immobilised onto the dextran-coated gold surface 
of a sensor chip and its interaction with a soluble analyte 
flowing through the dextran matrix is monitored by changes 
in refractive index which are proportional to mass increases 
resulting from the interaction. Collected sensorgrams can sub- 
sequently be used to estimate the association and dissociation 
rate constants, by either linearised transformation [9] or non- 
linear curve-fitting methods [10] using the BIAevaluation 2.1 
software (Pharmacia Biosensor). 
Here we report he use of SPR technology to investigate the 
interaction between p21Cipl and PCNA. We compare the 
results obtained by this approach with previous in vitro inter- 
action data and with in vivo interactions measured using the 
two-hybrid system in yeast. We report here the kinetic param- 
eters of the p21Cipl-PCNA interaction and demonstrate the 
use of this strategy to assay competitive peptides. Further- 
more, we show that a point mutation of PCNA that abolishes 
trimer formation [11] also totally impairs its interaction with 
p21Cipl, indicating that this complex formation is dependent 
on the oligomerisation state of PCNA. 
2. Materials and methods 
2.1. Materials 
The BIAcore system, CM5 research grade sensor chips, coupling 
reagents and HBS buffer were purchased from Pharmacia Biosensor 
(Uppsala, Sweden). E. coli and budding yeast growth media were 
from Biol01 Inc. (La Jolla, CA). Glutathione Sepharose was from 
Pharmacia (Uppsala, Sweden) and electrophoresis reagents from 
BioRad (Hercules, CA). 
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2.2. Protein purification 
Constructs expressing lutathione S-transferase fusion proteins 
were made as previously described [4] in the pGEX-KG vector. Pro- 
duction of recombinant proteins was achieved after induction with 0.4 
mM IPTG (isopropyl thiogalactoside) for 4 h at 37°C in Luria broth. 
GST-p21Cipl fusion proteins wild-type and ASM mutants were pro- 
duced in E. coli BL21(DE3)pLysE and purified from inclusion bodies 
as previously described [12]. GST-CTE, encoding the carboxy-term- 
inal half of p21Cipl (residues 75-164), was soluble and was therefore 
purified as follows: harvested cells were sonicated in PBS buffer (140 
mM NaC1, 2.7 mM KC1, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 
7.3) containing protease inhibitors (0.1 mM PMSF, 1 p.g/ml eupeptin, 
1 ~g/ml aprotinin and 10 gg/ml TPCK (tosyl phenylalanine chloro- 
methyl ketone)) and centrifuged at 27 000 × g for 30 rain. The super- 
natant was adjusted to 0.1% Triton X-100 and incubated with glu- 
tathione Sepharose for 3 h at 4°C. After three washes with 5-fold bed 
volume (50 mM Tris-HCl pH 8.0, 50 mM NaC1), GST-CTE was 
eluted with 50 mM Tris-HC1 (pH 8.0) containing 10 mM glutathione. 
All purified proteins were stored at -80°C until use. Wild-type PCNA 
and the Y114A mutant were purified exactly as described [11]. 
Protein concentrations were determined using the Bradford [13] 
assay (Bio-Rad). Purified proteins were resolved by SDS-polyacryl- 
amide gel electrophoresis according to Laemmli [14]. 
The two peptides used in the BIAcore assays were in a 5 mM 
solution in DMSO. Working solutions were made by dilution in 
HBS buffer (10 mM HEPES, pH 7.4, 150 mM NaCI, 3.4 mM 
EDTA, 0.005% Surfactant p-20) and filtered through 0.22 ~tm Millex 
GV filters (Millipore). 
2.3. Two-hybrid assay 
Plasmids pGBT9-CIPI and pGBT9-ASMx (x=the number of the 
respective mutant) were constructed by cloning the entire coding se- 
quences of wild-type or mutant p21CIP1 downstream and in frame 
with the GAL4 DNA-binding domain in the EcoRI and BamHI sites 
of pGBT9 cloning vector (Clontech); the plasmid pACT-PCNA, ex- 
pressing the human PCNA protein fused to the GAL4-activation 
domain in the pACT2 vector (Clontech), was kindly provided by I. 
Salles (Grenoble, France). For interaction assays, the yeast strain 
SFY526 (MATa, ura3-52, his3-200, ade2-101, lys2-801, trpl-901, 
leu2-3,112, can r, gal4-542, gal80-538, URA3::GALI-lacZ) [15] was 
transformed with equal quantities of pACT-PCNA and pGBT9- 
CIP1 or pGBT9-ASMx plasmids. Transformants were selected on 
SD synthetic medium minus Leu-Trp plates at 30°C and grown for 
2-3 days. Independent ransformants were grown overnight 
(OD600 = 1) in 5 ml of SD minus Leu-Trp medium at 30°C and [3- 
galactosidase activity was then measured on crude cellular extracts. 
Cells were collected by centrifugation, washed once in 1 ml of Z buffer 
(60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KC1, 1 mM MgSO4, 
40 mM 13-mercaptoethanol, 1 mM PMSF, pH 7.0) and disrupted in 
300 ~tl of Z buffer by vortexing with glass beads at 4°C for 2 min. A 
10 ~tl aliquot of this extract was used for the determination f protein 
concentration; assay for 13-galactosidase activity was initiated by the 
addition of 150 ~tl of o-nitrophenyl I]-D-galactopyranoside solution (4 
mg/ml in 0.1 M phosphate buffer pH 7.0) and subsequent incubation 
at 30°C until yellow color developed, and for 3 h maximal duration. 
The reaction was then stopped by the addition of 500 ~tl of 1 M 
Na2CO3 and tubes were stored on ice. Reaction mixtures were cen- 
trifuged briefly, and the OD420 of the supernatant was measured; [5- 
galactosidase activity in Miller units was calculated according to the 
Table 1 
List of the p21Cipl mutants used in this study and in vitro interac- 
tion with PCNA ~ 
Name Sequence % PCNA a 
p21 Wild-type 100 
ASM7 D52A 81 
ASM19 H152A, K154A, R155A, R156A 0 
p21CTE Amino acids 75-164 25 
GST Glutathione S-transferase 0 
The extent of interaction of these GST fusion proteins with PCNA 
was determined in an in vitro assay (see [4]), and is expressed as a 
percentage of binding relative to the interaction measured with wild- 
type p21Cipl. 
aOur unpublished ata and see also [4]. 
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Table 2 
Determination of the interaction between PCNA and p21Cipl mu- 
tant proteins using the two-hybrid assay in Saccharomyces cerevisiae 
Partners a I~-Galactosidase % of control 
activity b 
PCNA-bd 2.5 0 
PCNA-p21Cipl 425 100 
PCNA-ASM7 590 139 
PCNA-ASM19 156 36 
ad-ASM19 1.7 0 
~PCNA was in fusion with GAL4-activating domain (ad) and p21Cip 
was in fusion with GAL4 DNA-binding domain (bd). 
bl3-Galactosidase activity was determined as described in [19]. 
formula: units-OD420 ×380/t x P, where t=time of incubation (in 
min) and P=proteins added to Z buffer in mg. 
2.4. SPR analysis: Immobilisation procedure and buffers 
PCNA or GST-p21Cipl wild-type proteins were covalently coupled 
to the dextran of sensor chip CM5 research grade. The carboxyme- 
thylated dextran was first activated uring 3 to 5 rain. (5 tll min -1 
flow rate) with 0.1 M N-hydroxysuccinimide (NHS) and 0.4 M N- 
ethyl-N'-(dimethylaminopropyl)carbodiimide (EDC) in water. The li- 
gand was then injected through the reactive surface (30 ktl 0.14 ktM for 
PCNA, 20 ~tl 0.5 ktM for GST-p21Cipl) in 10 mM acetate buffer (pH 
4.5) with a continuous flow of HBS (5 I.tl/min). The residual NHS 
esters on the sensorchip surface were then deactivated over 6 rain 
with 1 M ethanolamine, pH 8.5, in water. Final regeneration of the 
matrix was performed with 0.1 N NaOH. 
2.5. Study of the interaction and calculation of constants 
Purified recombinant p21Cipl wild-type and mutant proteins, 
PCNA wild-type and the Y114A mutant, and peptides were diluted 
in HBS buffer. A 40 ].tl sample was injected over the PCNA or GST- 
p21Cipl coupled surface for 8 min at a 5 ~tl/min flow rate. Multiple 
injections at various concentrations were performed for each ligand. 
For each concentration a control injection was performed on an acti- 
vated-deactivated sensor chip. The sensorgrams were recorded and, 
after subtraction of the control, the data were fitted to a single site 
binding model by non-linear least-squares curve fitting using the 
BIAevaluation 2.1 software (Pharmacia Biosensor). The apparent dis- 
sociation rate constant korf was calculated by iterative fitting to first 
order model. For the association phase, we calculate ks (ks is the slope 
of the plot of instant rate dR/dt vs. R), at various concentrations (C) 
of analyte and the association rate constant kon was calculated by 
linear curve fitting of a plot of k~ vs. C. In control experiments per- 
formed with the GST moiety alone, no interaction with PCNA was 
found. 
3. Results 
3.1. p21Cipl -PCNA interaction in the yeast two-hybrid system 
The list of the p21Cipl  mutant  proteins used in this study is 
shown in Table 1. The level of interaction with PCNA was 
determined in vitro as already described [4] and was normal-  
ised to 100% with wild-type p21Cipl .  This set of p21 recom- 
binant proteins includes wild-type and mutant  sequences 
which are able to interact with PCNA and those which are 
not. Under  the experimental conditions of the in vitro assay 
that was used, mutant  ASM19 was totally unable to bind 
PCNA. The carboxy-terminal part of the protein (residues 
75-164) that comprises the PCNA-b inding domain [4,5] only 
partially interacted with PCNA (25%). The ASM7 mutant  
that does not interact with CDK2 [4] was not significantly 
affected in its interaction with PCNA. 
To investigate further the interaction between the wild-type 
and mutant  p21Cipl  and PCNA, we first used a two-hybrid 
assay in the budding yeast Saccharomyces cerevisiae. Wild- 
type or relevant mutants  of p21Cipl ,  and PCNA, were fused 
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Fig. 1. SDS-PAGE of the proteins used in this study. Purified pro- 
teins were subjected to SDS-PAGE (12.5% acrylamide) and Coo- 
massie stained. Wild-type p21Cipl (WT) (1 p.g), mutants p21Cipl 
(ASM19 (1 ktg) and ASM7 (1 ~tg)), proliferating cell nuclear antigen 
(PCNA) (1 ~tg) and PCNA mutant Yll4A (2 ~tg), are shown. 
Molecular mass markers (M) are 97, 67, 43, 30, 20 and 14 kDa. 
to the DNA-binding domain and to the activation domain of 
the yeast transcriptional ctivator GAL4, respectively. Plas- 
mids encoding these fusion proteins were cotransformed into 
the yeast strain SFY526, carrying the lacZ reporter gene un- 
der the control of GAL4-binding sites. A quantitative deter- 
mination of the interaction between the two proteins was 
performed by measuring ~-galactosidase activity on total cell 
lysates. The results of a typical experiment are reported in 
Table 2. No trans-activation was observed when the fusion 
between the GAL4-activating domain and PCNA was co-ex- 
pressed with GAL4 DNA-binding domain (bd) alone. Simi- 
larly, fusion of any of the p21Cipl mutants with GAL4 DNA- 
binding domain was unable to activate [3-galactosidase tran- 
scription when co-expressed with GAL4-activating domain 
alone (last line of Table 2 and data not shown). Interaction 
between PCNA and wild-type p21Cipl was very strong, re- 
sulting in high ~-galactosidase activity. As expected, mutant 
ASM7 which we previously identified in vitro as unable to 
bind CDK2 interacted normally with PCNA. The latter inter- 
action was moreover slightly stronger than that found with 
the wild-type p21Cipl (139%). Mutant ASM19 which in vitro 
was totally unable to bind PCNA was found in two-hybrid 
assay to be still able to interact although more weakly than 
the wild-type (36%). These results provide valuable informa- 
tion (see Section 4), however, the two-hybrid assay does not 
allow an exclusive and quantitative determination f the inter- 
action between two proteins. 
3.2. p21Cip1-PCNA interaction analyzed with SPR 
To evaluate the kinetic parameters of interaction, we used 
the SPR technology. Purified wild-type PCNA (see Section 2) 
was immobilised onto CM5 BIAcore sensor chip. The 
p21Cipl protein, the mutant forms (ASM7, ASM19) and 
the truncated protein (CTE) were purified as described in 
Section 2 to approx. 90-95% homogeneity (Fig. 1). These 
proteins were injected at different concentrations onto the 
immobilised PCNA ligand (2000 RU) and the sensorgrams 
were recorded (data not shown). Dissociation (koff) and asso- 
ciation (ko~) constants were derived from the data collected 
with concentration ranging from 5 to 20 ~tM using a single site 
binding model with the BIAevaluation 2.1 software. The ap- 
parent dissociation and association constants are reported in 
Table 3. The calculated apparent equilibrium constant KD for 
wild-type p21Cipl was 3.2 x 10 -7 M. For the mutant ASM7, 
which binds to PCNA in an in vitro assay and in the two- 
hybrid system, the KD value was similar to that of the wild- 
type (2.4 x 10 -7 M). A considerable d crease in the interaction 
between mutant ASM19 and PCNA was found, with a KD 
about 100-fold lower than that of wild-type p21Cipl 
(3.9 x 10 -s M). Surprisingly, the carboxy-terminal domain of 
p21Cipl that is known to interact with PCNA also displayed 
a lowered interaction constant for PCNA (KD: 4.1 X 10 -6 M), 
suggesting that the two functional domains of p21Cipl are 
not fully independent. 
Thus, the SPR technology allows a fine discrimination be- 
tween the binding properties of several mutants and further- 
more gives access to essential kinetic data. 
3.3. Interaction between p21 and PCNA is dependent on the 
trimerisation of PCNA 
The importance of the trimerisation of PCNA for its inter- 
action with other proteins has recently been shown using a 
tyrosine to alanine mutation that is unable to oligomerise [11]. 
We have comparatively investigated the interaction properties 
of PCNA and Y114A-PCNA with p21Cipl using BIAcore. 
Wild-type p21Cipl was covalently coupled on a sensor chip 
and both forms of PCNA were injected. As described above 
and also shown in Fig. 2, wild-type PCNA interacted with 
p21Cipl that was coated on the sensorchip matrix with a 
calculated KD of 3.0X 10 -7 M. Mutant Yl l4A-PCNA did 
not interact at all with p21Cipl, and consequently no associa- 
tion constant could be determined. 
3.4. Competing peptide 
We next asked whether the BIAcore system might be used 
in order to screen molecules that may inhibit the interaction 
between p21Cipl and PCNA. To address this question, we 
used a synthetic p21-1ike 20met peptide that has been shown 
to interact with PCNA [5]. A 19-mer p21Cipl unrelated pep- 
tide (YIVPEDKREMWMACIKEAA) was used as a control. 
In the first experiment, a 20/tM concentration f either pep- 
tide was continuously passed in the flow on the PCNA sensor 
chip, then 40 ~tl of 20 ~tM wild-type p21Cipl were injected (5 
~tl/min). The sensorgrams obtained in that experiment are 
Table 3 
Interaction between PCNA and p21Cipl: Determination of the as- 
sociation and dissociation constants ~ 
koff (s -1) ko, (M -1 S -1) KD (M) b 
Wild-type p21 3.7 X 10 -4 1.1 X 103 3.2 × 10 -7 
ASM7 2.7X 10 -4 1.1X 103 2.4X 10 -7 
ASM19 3.9X 10 -3 1.0X 102 3.9X 10 -5 
CTE 8.7x 10 -3 2.1 x 103 4.1 × 10 -s 
~Dissociation (koff) and association (ko,) rate constants were calcu- 
lated using the BIAevaluation 2.1 software (Pharmacia) from data 
collected from multiple reproducible experiments (see text). 
bThe equilibrium constant KD is calculated from the ratio koff/kon 
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Fig. 2. SPR experiments indicate that p21Cipl interacts with wild- 
type PCNA but not with the Yll4A-PCNA mutant. Sensorgrams 
recorded after the injection of 40 ~tl of a 1 pM solution of wild-type 
PCNA (e) or Yll4A PCNA mutant (m) on a sensor chip on which 
GST-p21Cip1 was immobilised. A control sensorgram recorded after 
injection of the same analytes on a blank sensor chip has been sub- 
tracted for each curve, 
shown in Fig. 3A. The control peptide injected into the flow 
buffer had no effect on the association and dissociation con- 
stant (calculated K~ was 2.9x 10 -~ M). However, when the 
p2 l-like 20-mer peptide was used, the interaction with PCNA 
was completely abolished. The upward shift of the baseline is 
due to the difference in refringence, and is independent of the 
actual binding between the analyte and the ligand. 
We next performed the converse xperiment where p21Cipl 
was immobilised on the sensor chip and PCNA was used as 
the analyte. A pre-incubation between PCNA and a 5 M 
excess of either the control or the p21-1ike 20-mer peptide 
was performed before the injection. In a control experiment, 
we demonstrated that the p21-1ike 20-mer peptide did not 
interact at all with immobilised p21Cipl (not shown). As 
shown in Fig. 3B, the p21-1ike 20-mer peptide completely 
abolished interaction between PCNA and p21Cipl, while 
the control peptide had no effect. 
4. Discussion 
We have investigated the interaction between the cyclin-de- 
pendent kinase inhibitor p21Cipl and proliferating cell nucle- 
ar antigen (PCNA). A recent study reported a good correla- 
tion between the strength of the interactions as predicted by 
the two-hybrid approach and the in vitro determination f the 
affinity, permitting discrimination between high-, intermedi- 
ate-, and low-affinity interactions [16]. Therefore, we decided 
first to compare the interaction of mutant proteins with 
PCNA using the two-hybrid assay in S. cerevisiae. These re- 
sults were of particular interest, since mutant ASM19, that 
does not bind PCNA in an in vitro assay, was found to inter- 
act efficiently in this system (36% of the wild-type). This 
strongly suggests that, in this type of in vivo assay, unknown 
stabilising partners may cooperate to allow an interaction to 
occur. This point should be investigated further. Mutant 
ASM7 was found to bind PCNA more strongly than the 
wild-type. As demonstrated by the determination f the KD 
using SPR, this result is not due to an increase in affinity, but 
rather to a peculiar property of that mutant when expressed in 
yeast. A similar observation was made when ASM7 was over- 
expressed in the fission yeast Schizosaccharomyces pombe [17]. 
In that system, ASM7 mutant was shown to be more efficient 
at binding PCNA and consequently more active in stopping 
cell proliferation. The molecular basis of that result remains 
to be investigated. 
We conclude that the two-hybrid assay does not provide a 
quantitative characterisation f the interaction parameters be- 
tween two proteins and that it is clearly influenced by other in 
vivo molecular events. We therefore decided to make use of 
SPR technology to investigate these interactions further. 
Three important conclusions can be drawn from the SPR 
data. (i) First, the interaction constant between PCNA and 
p21Cipl could be calculated and the effects of mutations of 
p21Cipl on these parameters quantitated. For instance, mu- 
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Fig. 3. SPR experiments indicate that peptides can compete in the 
p21Cipl-PCNA interaction. (A) The p21Cipl-like 20-mer peptide 
(KRRQTSMTDFYHSKRRLIFS, ,) or the unrelated peptide (YIV- 
PEDKREMWMACIKEAA, A) were added (20 ktM) to the buffer 
flow passing over a sensor chip on which PCNA was immobilised. 
40 p.1 of a 20 ktM wild-type GST-p21Cipl solution containing 20 
~tM p21-1ike 20-mer peptide, control peptide or buffer (zx) was in- 
jected. (B) A mixture of a 5-fold molar excess of peptide and 
PCNA (0.3 IxM) was incubated for 10 min and 40 ~tl were injected 
onto a sensor chip on which GST-p21Cipl was immobilised. (zx) 
No peptide, ('k) peptide p21Cipl-like 20-mer. 
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equilibrium constant as compared to wild-type p21Cipl. Both 
the association, kon, and the dissociation, koff, rate constants 
were affected. This result is in full agreement with the lack of 
interaction in the in vitro assay that we initially used to screen 
the mutants. However, this result demonstrates that in fact the 
interaction is not completely abolished, indicating that other 
residues of p21Cipl, such as Met-147 and Phe-150, are also 
important for this interaction [5]. The carboxy-terminal do- 
main of p21Cipl, that is sufficient o bind PCNA, also dis- 
played a lowered affinity for PCNA. This result strongly sug- 
gests that the two domains of p21Cipl that allow separate 
interaction with CDK2 and PCNA are not fully independent. 
(ii) Second, we clearly demonstrated that a mutant of 
PCNA (Yll4A), that is unable to trimerise [11], does not 
interact at all with p21Cipl. The complete lack of interaction 
strongly suggests that binding of p21Cipl to PCNA is 
strongly dependent upon trimerisation of PCNA. 
(iii) Third, we confirm here that a 20-mer peptide that mi- 
micks the carboxy-terminal domain of p21 is able to bind 
PCNA [5]. Using this peptide we clearly demonstrated that 
the BIAcore system can be used to perform a screen for mo- 
lecules that might inhibit interaction between PCNA and 
p21Cipl. A similar approach could also be used to search 
for molecules that enhance this interaction. 
In conclusion, SPR technology offers the possibility of 
studying the interaction parameters between biomolecules in 
great detail. As shown here for p21Cipl and PCNA, it allows 
the calculation of association and dissociation constants that 
characterise the interaction, information that is not usually 
provided by the most commonly used assays. There are sev- 
eral methods for analysing the complex data collected by 
SPR, the most commonly used being available in BIAcore's 
software package. Discussions on their validity have appeared 
in the literature ([18] and references therein). In this report, we 
focused on the specific advantages of SPR as compared to 
other approaches used when studying interactions between 
cell cycle regulatory proteins. Our results clearly demonstrate 
that this technology provides invaluable and novel informa- 
tion on these interactions. 
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